ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Nov 7, 2024
Gilead Raises Revenue and Non-GAAP Diluted EPS Guidance
Image Source: Gilead. At the end of the quarter, Gilead had $5 billion in cash and marketable securities compared to $8.4 billion at the end of the year, the decline primarily due to its $3.9 billion acquisition of CymaBay Therapeutics. For the full year 2024, Gilead raised its guidance for product sales to the range of $27.8-$28.1 billion, up from $27.1-$27.5 billion previously. Non-GAAP diluted earnings per share is now targeted in the range of $4.25-$4.45, up from $3.60-$3.90 previously. We liked Gilead’s revenue growth in the quarter, as well as its raised financial outlook for 2024. The high end of our fair value estimate range stands at $111 per share.
Sep 19, 2024
Brain Teaser - Reflexive versus Reflective
Image: Amy Leonard. Valuation multiples tend to trigger the reflexive side of our brain, and we process the multiples through anchoring. On the other hand, enterprise valuation, or the process required to answer the questions (in this article) correctly, shows that our reflexive process can be quite incorrect at times. In fact, cognitive biases such as anchoring can completely trip us up into missing out on truly undervalued companies that may have high P/E ratios while baiting us into value traps with low P/E ratios.
Aug 25, 2024
Latest Report Updates
Check out the latest report updates on the site.
Aug 19, 2024
Gilead Raises Non-GAAP Diluted Earnings Outlook for 2024
Image Source: Gilead. Looking to full-year 2024, Gilead expects total product sales of $27.1-$27.5 billion, unchanged from its prior outlook. Non-GAAP diluted earnings per share is now targeted in the range of $3.60-$3.90, compared to $3.45-$3.85 previously. At the end of the quarter, Gilead had $2.8 billion in cash and cash equivalents, which was down from the $8.4 billion mark as of the end of last year due to its $3.9 billion acquisition of CymaBay Therapeutics and a $1.75 billion repayment of senior notes. All told, we liked Gilead's second quarter results and its raised non-GAAP earnings per share guidance. Shares yield 4.2% at the time of this writing.
Aug 9, 2024
Paper: Value and Momentum Within Stocks, Too
Abstract: This paper strives to advance the field of finance in four ways: 1) it extends the theory of the “The Arithmetic of Active Management” to the investor level; 2) it addresses certain data problems of factor-based methods, namely with respect to value and book-to-market ratios, while introducing price-to-fair-value ratios in a factor-based approach; 3) it may lay the foundation for academic literature regarding the Valuentum, the value-timing, and ultra-momentum factors; and 4) it walks through the potential relative outperformance that may be harvested at the intersection of relevant, unique and compensated factors within individual stocks.
Jun 10, 2024
Update: Frequently Asked Questions About Valuentum Securities, Inc.
Valuentum (val∙u∙n∙tum) [val-yoo-en-tuh-m] Securities Inc. is an independent investment research publisher, offering premium equity reports and dividend reports, as well as commentary across all sectors/companies, a Best Ideas Newsletter (spanning market caps, asset classes), a Dividend Growth Newsletter, modeling tools/products, and more. Independence and integrity remain our core, and we strive to be a champion of the investor. Valuentum is based in the Chicagoland area. Valuentum is not a money manager, broker, or financial advisor. Valuentum is a publisher of financial information. We address a number of questions from both subscribers and visitors to our site.
Jun 1, 2024
Latest Report Updates
Check out the latest report updates on the website.
Apr 3, 2024
Gilead’s 4%+ Dividend Yield Covered Nicely with Free Cash Flow
Image: Gilead’s coverage of its dividend with free cash flow remains rock-solid. What we like about Gilead is that the company remains a very strong free cash flow generator, with the measure coming in at $7.4 billion during 2023 versus dividend payments of $3.8 billion. On a free cash flow coverage basis, Gilead 4%+ dividend yield looks rock-solid, and for this, we think investors may be wise to get paid to wait for upcoming catalysts within Gilead’s HIV and oncology pipeline.
Mar 21, 2024
Pfizer 6% Dividend Yield Speaks of Considerable Risk, Free Cash Flow Coming Up Short
Image: Pfizer’s shares have been under considerable pressure the past few years. Though we are positive on Pfizer’s turnaround, its Dividend Cushion ratio of 0.3 is not to be taken lightly (any ratio below 1 indicates heightened risk of a dividend cut). Income-oriented investors seeking a turnaround story may be interested in Pfizer, but we’re staying on the sidelines. We’ll continue to monitor developments at the pharma giant, especially as patents on several of its major drugs approach expiration. Shares yield ~6% at the time of this writing.
Mar 17, 2024
Latest Report Updates
Check out the latest report updates on the website.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.